背景:肿瘤治疗场(TTFields)是中断癌细胞过程的交变电场。TTFields疗法被批准用于复发性胶质母细胞瘤(rGBM),和新诊断(nd)GBM(同时使用替莫唑胺治疗ndGBM;美国),和IV级神经胶质瘤(欧盟)。我们提出了一个最新的全球,使用TTFields治疗的CNS恶性肿瘤患者的上市后监测安全性分析。
方法:从北美患者的常规上市后活动中收集安全性数据,欧洲,以色列,和日本(2011年10月-2022年10月)。不良事件(AE)按年龄分层,性别,和诊断。
结果:总体而言,包括25,898例患者(诊断:ndGBM[68%],rGBM[26%],间变性星形细胞瘤/少突胶质细胞瘤[4%],其他中枢神经系统恶性肿瘤[2%])。中位(范围)年龄为59(3-103)岁;66%的患者为男性。大多数(69%)患者年龄为18-65岁;0.4%<18岁;30%>65岁。18,798(73%)和14,599(56%)患者发生了全因和TTField相关的AE,分别。最常见的治疗相关的AE是皮下反应(43%),电感觉(刺痛;14%),和热感觉(温暖;12%)。与治疗相关的皮肤反应在儿科患者中具有可比性(39%),成人(42%)和老年人(45%)组,在男性(41%)和女性(46%)中;在诊断亚组中相似(ndGBM,46%;rGBM,34%;间变性星形细胞瘤/少突胶质细胞瘤,42%;其他,40%)。未报告TTFelds相关的系统性AE。
结论:从长远来看,对>25,000例患者的真实世界分析显示,中枢神经系统恶性肿瘤患者对TTField的耐受性良好.大多数治疗相关的AE是局部可控的,非严重皮肤事件。TTFields治疗的安全性在各个亚组之间保持一致(年龄,性别,和诊断),表明其广泛的适用性。
BACKGROUND: Tumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for recurrent glioblastoma (rGBM), and newly-diagnosed (nd) GBM (with concomitant temozolomide for ndGBM; US), and for grade IV glioma (EU). We present an updated global, post-marketing surveillance safety analysis of patients with CNS malignancies treated with TTFields therapy.
METHODS: Safety data were collected from routine post-marketing activities for patients in North America, Europe, Israel, and Japan (October 2011-October 2022). Adverse events (AEs) were stratified by age, sex, and diagnosis.
RESULTS: Overall, 25,898 patients were included (diagnoses: ndGBM [68%], rGBM [26%], anaplastic astrocytoma/oligodendroglioma [4%], other CNS malignancies [2%]). Median (range) age was 59 (3-103) years; 66% patients were male. Most (69%) patients were 18-65 years; 0.4% were < 18 years; 30% were > 65 years. All-cause and TTFields-related AEs occurred in 18,798 (73%) and 14,599 (56%) patients, respectively. Most common treatment-related AEs were beneath-array skin reactions (43%), electric sensation (tingling; 14%), and heat sensation (warmth; 12%). Treatment-related skin reactions were comparable in pediatric (39%), adult (42%), and elderly (45%) groups, and in males (41%) and females (46%); and similar across diagnostic subgroups (ndGBM, 46%; rGBM, 34%; anaplastic astrocytoma/oligodendroglioma, 42%; other, 40%). No TTFields-related systemic AEs were reported.
CONCLUSIONS: This long-term, real-world analysis of > 25,000 patients demonstrated good tolerability of TTFields in patients with CNS malignancies. Most therapy-related AEs were manageable localized, non-serious skin events. The TTFields therapy safety profile remained consistent across subgroups (age, sex, and diagnosis), indicative of its broad applicability.